Company intelligence / Profile preview

Advanced Influenza Technologies

Lutz, Florida, United States

Ownership: Private
Development stage: Other

Overview

Advanced Influenza Technologies was a biotechnology company focused on the development of DNA-based influenza vaccines. Incorporated in Florida in 2006, the company held an exclusive license for a DNA-based influenza vaccine candidate developed at the University of Massachusetts Medical School. Shortly after its formation, it was acquired by CytoDyn Inc. in July 2006 to bolster CytoDyn's portfolio of infectious disease treatments. However, the entity was later administratively dissolved in 2009 as CytoDyn shifted its focus toward its lead monoclonal antibody programs.

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccine
Industry: Biotech

Partnerships

University of Massachusetts Medical School

Beyond the preview

Go deeper on Advanced Influenza Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Influenza Technologies.

Explore the full profile